Latest:
Dr Shah on Responses With Pembrolizumab Plus Chemo By PD-1 Status in Esophageal Cancer
Manish A. Shah, MD, discusses how pembrolizumab with chemotherapy impacts immune responses in advanced esophageal cancer according to PD-L1 status.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Manju P. Paul, MD
Latest:
Dr. Paul Discusses the Pulmonologist's Role in Managing Patients With Lung Cancer
Manju P. Paul, MD, assistant professor of medicine at Upstate University Hospital, discusses the pulmonologist’s role as part of the multidisciplinary approach in treating patients with non–small cell lung cancer (NSCLC).
Manuel Hidalgo, MD, PhD
Latest:
Dr. Hidalgo Discusses the Phase III TRYbeCA1 Trial in Pancreatic Cancer
Manuel Hidalgo, MD, PhD, professor of medicine, Harvard Medical School, chief, Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the phase III TRYbeCA1 trial in patients with advanced pancreatic adenocarcinoma.
Marc Ernstoff, MD
Latest:
Dr. Ernstoff Discusses Nivolumab and Ipilimumab in Advanced Melanoma
Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.
Marc Peeters, MD, PhD
Latest:
Dr. Peeters Discusses the Efficacy and Safety of Panitumumab Versus Cetuximab in CRC
Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the efficacy and safety of panitumumab versus cetuximab as seen in the ASPECCT trial in colorectal cancer (CRC).
Marcela V. Maus, MD, PhD
Latest:
Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and Beyond
Chimeric antigen receptor T-cell therapy is an immunotherapy in which the patient's own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient.